A detailed history of Two Sigma Investments, LP transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 135,122 shares of PLRX stock, worth $1.66 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
135,122
Previous 245,572 44.98%
Holding current value
$1.66 Million
Previous $2.64 Million 42.63%
% of portfolio
0.0%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.52 - $14.35 $1.16 Million - $1.58 Million
-110,450 Reduced 44.98%
135,122 $1.51 Million
Q2 2024

Aug 14, 2024

BUY
$10.58 - $15.61 $1.47 Million - $2.16 Million
138,548 Added 129.46%
245,572 $2.64 Million
Q1 2024

May 15, 2024

BUY
$14.14 - $19.59 $1.51 Million - $2.1 Million
107,024 New
107,024 $1.59 Million
Q3 2023

Nov 14, 2023

SELL
$14.58 - $20.15 $3.16 Million - $4.36 Million
-216,577 Reduced 67.83%
102,709 $1.78 Million
Q2 2023

Aug 14, 2023

SELL
$18.12 - $30.56 $1.76 Million - $2.98 Million
-97,364 Reduced 23.37%
319,286 $5.79 Million
Q1 2023

May 15, 2023

BUY
$18.73 - $36.26 $3.73 Million - $7.22 Million
199,205 Added 91.61%
416,650 $11.1 Million
Q4 2022

Feb 14, 2023

SELL
$17.0 - $25.43 $519,554 - $777,191
-30,562 Reduced 12.32%
217,445 $4.2 Million
Q3 2022

Nov 14, 2022

BUY
$7.67 - $24.23 $1.79 Million - $5.67 Million
234,007 Added 1671.48%
248,007 $5.18 Million
Q2 2022

Aug 15, 2022

SELL
$4.11 - $8.75 $457,352 - $973,682
-111,278 Reduced 88.82%
14,000 $112,000
Q1 2022

May 16, 2022

BUY
$7.01 - $14.1 $65,256 - $131,256
9,309 Added 8.03%
125,278 $878,000
Q4 2021

Feb 14, 2022

BUY
$12.27 - $18.26 $1.42 Million - $2.12 Million
115,969 New
115,969 $1.57 Million

Others Institutions Holding PLRX

About PLIANT THERAPEUTICS, INC.


  • Ticker PLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,682,000
  • Market Cap $600M
  • Description
  • Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...
More about PLRX
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.